# IQVIA (IQV) Forecast Calculator

Interactive five-year financial forecast and DCF for IQVIA. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/iqvia/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 11088000000 | 835000000 | 1979000000 | 191000000 |
| 2022 | 11359000000 | 1343000000 | 2018000000 | 279000000 |
| 2023 | 13874000000 | 2302000000 | 2657000000 | 966000000 |
| 2024 | 14410000000 | 1586000000 | 2929000000 | 1091000000 |
| 2025 | 14984000000 | 1500000000 | 3102000000 | 1358000000 |

## Frequently asked questions

### What services does IQVIA provide to the life sciences industry?

IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences sector. The company leverages its proprietary CORE database, containing over 1.2 billion non-identified patient records, to accelerate clinical trials and commercialize drugs. Its business segments include Research & Development Solutions, Technology & Analytics Solutions, and Contract Sales & Medical Solutions.

### How does IQVIA generate its revenue, and what are its primary business segments?

IQVIA generates revenue primarily through its Research & Development Solutions (approximately 55%), Technology & Analytics Solutions (approximately 41%), and Contract Sales & Medical Solutions (approximately 4%) segments. Key revenue drivers include clinical trial backlog conversion and healthcare data subscription renewals. The company operates globally, with significant revenue contributions from the Americas, EMEA, and Asia-Pacific regions.

### What is the assumed capital expenditure as a percentage of revenue in the IQVIA financial model?

The financial model for IQVIA assumes capital expenditure (Capex) as a percentage of revenue to be approximately 4.9%. This investment primarily supports continuous enhancements to the proprietary CORE database and clinical trial management software platforms. A significant portion of this capex is allocated to capitalized software development, representing growth-oriented investment.

### What are the key inputs considered when evaluating IQVIA's equity valuation in the financial model?

The IQVIA financial model evaluates equity valuation by forecasting key operational drivers such as clinical trial backlog conversion and healthcare data subscription renewals. It also considers the allocation of free cash flow between debt repayment and share repurchases to determine the company's value and debt service capacity. The model covers a forecast horizon from FY2026 through FY2030.

### Can I download an Excel financial model for IQVIA, and what is its forecast horizon?

Yes, an Excel financial model for IQVIA is available for download, providing a detailed forecast of the company's financials. This model covers a forecast horizon from Fiscal Year 2026 through Fiscal Year 2030. It is designed to evaluate IQVIA's equity valuation and debt service capacity.

### Why do goodwill and intangible assets represent such a large portion of IQVIA's total assets?

Goodwill and intangible assets typically constitute 65% to 70% of IQVIA's total assets, reflecting the company's extensive acquisitive history. IQVIA is a serial bolt-on acquirer, focusing on niche data sets, healthcare technology, and specialized clinical capabilities. This strategy has led to a balance sheet dominated by these intangible assets.